Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Latest From Andrew McConaghie

COVID-19 Vaccine Gives Moderna $18bn Launchpad Into HIV Vaccine, Cancer Therapies

A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.

Companies Commercial

CEOs Face Grilling On Vaccine Supply In EU

AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.

Companies Commercial

Real-World Data Confirm Pfizer and AZ COVID-19 Vaccine Efficacy – And Bolster UK Dosing Policy

Observational studies from the National Health Service show encouraging signs for the UK’s vaccination program.

Commercial Companies

Lilly Broadens Its CNS Reach With Rigel RIPK1 Deal

The RIPK1 inhibitor class has yet to reach proof-of-concept, but could bolster Lilly’s dogged pursuit of progress in Alzheimer’s disease.

BioPharmaceutical Commercial

Stung By COVID Critics, EU Looks To BARDA-Style Agency To Act Faster On Variants

The European Commission wants to learn from mistakes made in the COVID-19 crisis and to create an end-to-end system to co-ordinate funding, clinical research and manufacturing of vaccines.

Europe Clinical Trials

Pfizer And Moderna Reap Rewards Of Expanded US And EU Deals

The two rival mRNA vaccines are proving attractive in the face of new variants, and could dominate once SARS-CoV2 enters the ‘endemic’ stage.

Commercial Companies
See All
UsernamePublicRestriction

Register